Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:49 UTC |
---|
HMDB ID | HMDB0014987 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Methylphenobarbital |
---|
Description | Methylphenobarbital, also known as mebaral or mephobarbitone, belongs to the class of organic compounds known as barbituric acid derivatives. Barbituric acid derivatives are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability.1935 – Mebaral was introduced by Winthrop Pharmaceuticals.2001 – Methylphenobarbital discontinued in the UK.2003 – Mebaral was acquired by Ovation Pharmaceuticals (a specialty pharmaceutical company that acquired under-promoted branded pharmaceutical products).2009 – Ovation was acquired by Lundbeck, which now markets Mebaral.2012 – Lundbeck announced that they were abandoning the product in the US as of January 6, 2012. Methylphenobarbital is a drug which is used for the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy. The last available tablets bore an expiration date of March 31, 2012, and the drug will no longer be available in the US when supplies are depleted. Methylphenobarbital is a very weakly acidic compound (based on its pKa). The stated reason was because "the company thoroughly evaluated all avenues for keeping Mebaral available to patients, but ultimately concluded that no matter what steps they [i.e. Lundbeck] took, patients would be forced to transition to a new therapy."The company further stated in a letter on its website that under the FDA's Unapproved Drugs Initiative, FDA is no longer willing to allow the drug to be grandfathered. Methylphenobarbital is a potentially toxic compound. A new drug application would have needed to have been submitted to gain marketing approval, which would have taken an estimated five years, during which time patients would be required to change their therapies in any case. Symptoms of overdose of mephobarbital include confusion, decrease in or loss of reflexes, somnolence, fever, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness. |
---|
Structure | CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1 InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18) |
---|
Synonyms | Value | Source |
---|
1-Methylphenobarbital | ChEBI | 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione | ChEBI | 5-Ethyl-1-methyl-5-phenyl-pyrimidine-2,4,6-trione | ChEBI | 5-Ethyl-1-methyl-5-phenylbarbituric acid | ChEBI | Mebaral | ChEBI | Mephobarbitone | ChEBI | Methylphenobarbitalum | ChEBI | Metilfenobarbital | ChEBI | N-Methylphenobarbital | ChEBI | 5-Ethyl-1-methyl-5-phenylbarbitate | Generator | 5-Ethyl-1-methyl-5-phenylbarbitic acid | Generator | Mephobarbital | HMDB | Methyl phenobarbitone | HMDB | Methylphenobarbitonum | HMDB | Methylphenolbarbital | HMDB | Methylphenylbarbituric acid | HMDB | Metilfenobarbitale | HMDB | N-Ethylmethylphenylbarbituric acid | HMDB | N-Methylethylphenylbarbituric acid | HMDB | N-Methylphenolbarbitol | HMDB | Methylphenobarbitone | HMDB | Sanofi synthelabo brand OF mephobarbital | HMDB | Prominal | HMDB | Sanofi brand OF mephobarbital | HMDB | Methylphenobarbital | ChEBI |
|
---|
Chemical Formula | C13H14N2O3 |
---|
Average Molecular Weight | 246.2619 |
---|
Monoisotopic Molecular Weight | 246.100442324 |
---|
IUPAC Name | 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione |
---|
Traditional Name | methylphenobarbital |
---|
CAS Registry Number | 115-38-8 |
---|
SMILES | CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1 |
---|
InChI Identifier | InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18) |
---|
InChI Key | ALARQZQTBTVLJV-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as barbituric acid derivatives. Barbituric acid derivatives are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazines |
---|
Sub Class | Pyrimidines and pyrimidine derivatives |
---|
Direct Parent | Barbituric acid derivatives |
---|
Alternative Parents | |
---|
Substituents | - Barbiturate
- Ureide
- N-acyl urea
- Monocyclic benzene moiety
- 1,3-diazinane
- Benzenoid
- Dicarboximide
- Urea
- Carbonic acid derivative
- Carboxylic acid derivative
- Azacycle
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Carbonyl group
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 176 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.71 g/L | Not Available | LogP | 1.84 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Methylphenobarbital,1TMS,isomer #1 | CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N([Si](C)(C)C)C1=O | 1833.0 | Semi standard non polar | 33892256 | Methylphenobarbital,1TMS,isomer #1 | CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N([Si](C)(C)C)C1=O | 2057.9 | Standard non polar | 33892256 | Methylphenobarbital,1TMS,isomer #1 | CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N([Si](C)(C)C)C1=O | 2651.2 | Standard polar | 33892256 | Methylphenobarbital,1TBDMS,isomer #1 | CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2103.4 | Semi standard non polar | 33892256 | Methylphenobarbital,1TBDMS,isomer #1 | CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2306.4 | Standard non polar | 33892256 | Methylphenobarbital,1TBDMS,isomer #1 | CCC1(C2=CC=CC=C2)C(=O)N(C)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2732.1 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Methylphenobarbital EI-B (Non-derivatized) | splash10-014i-7890000000-2901bd43c9c369accc5e | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Methylphenobarbital EI-B (Non-derivatized) | splash10-014i-7890000000-2901bd43c9c369accc5e | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methylphenobarbital GC-MS (Non-derivatized) - 70eV, Positive | splash10-014i-1960000000-03c5912fae96e516bc08 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methylphenobarbital GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methylphenobarbital GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 10V, Positive-QTOF | splash10-0002-0090000000-5efc4c40b94c015f15d1 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 20V, Positive-QTOF | splash10-00os-0930000000-00256f4ed6f9589accfb | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 40V, Positive-QTOF | splash10-014l-8900000000-852f79784f92a016b588 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 10V, Negative-QTOF | splash10-0f6t-4190000000-7afe5dafc1ac46950ae9 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 20V, Negative-QTOF | splash10-05fr-5900000000-adbe9ddcf8d5310392d5 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 40V, Negative-QTOF | splash10-0006-9400000000-e18ddad976005362cdce | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 10V, Positive-QTOF | splash10-0002-0090000000-c3b5328faa9ccd492274 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 20V, Positive-QTOF | splash10-014i-1940000000-83b4742c95ac40de815f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 40V, Positive-QTOF | splash10-00kf-9700000000-70a6a2b92d607f53d798 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 10V, Negative-QTOF | splash10-0002-0090000000-bd60669c03ea828062a5 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 20V, Negative-QTOF | splash10-0006-9320000000-d8726243263b97488adb | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methylphenobarbital 40V, Negative-QTOF | splash10-0006-9300000000-fb4279919738a6bc3b7c | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|